Fig. 7

Apoe knockdown via intrathecal administration of Apoe antisense oligonucleotide (ASO) suppresses complete Freund’s adjuvant (CFA)-induced pain hypersensitivity. Apoe ASO was intrathecally administered 3 days and 1 h before CFA treatment. The behavioral tests were performed before Apoe ASO treatment and at 2 h and on days 1 and 3 post-CFA treatment. A–F The effect of Apoe ASO on CFA-induced pain hypersensitivity to 0.16-g von Frey filament (A, D), 0.4-g von Frey filament (B, E), and thermal stimuli (C, F) on the ipsilateral (A–C) and contralateral sides (D–F) after CFA treatment. N = 5–11 mice/group. ^****p < 0.0001 and ^***p = 0.0006 compared with phosphate-buffered saline (PBS) and CFA-treated mice at 2 h post-treatment; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001, ^####p < 0.0001 compared with CFA and PBS-treated mice. Two-way analysis of variance, followed by Tukey’s post-hoc test. G The effect of Apoe ASO on Apoe expression in the spinal dorsal horn. N = 6 mice/group. ^**p = 0.0013 compared with CFA and PBS-treated mice (two-tailed unpaired Student’s t-test)